Contributors

Edward D.Bashaw Division of Pharmaceutical Evaluation III, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Eva Gil Berglund Medical Products Agency, Uppsala, Sweden

Carin Bergquist Medical Products Agency, Uppsala, Sweden

Brian P.Booth Division of Pharmaceutical Evaluation I, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Jyoti Chawla University of Washington, Seattle, Washington, U.S.A.

Dale P.Conner Division of Bioequivalence, Office of Generic Drugs, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Barbara M.Davit Division of Bioequivalence, Office of Pharmaceutical Science, Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Suresh Doddapaneni Division of Pharmaceutical Evaluation II, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Monica Edholm Medical Products Agency, Uppsala, Sweden

Marie Gärdmark Medical Products Agency, Uppsala, Sweden

Jogarao V.S.Gobburu Division of Pharmaceutical Evaluation I, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Shiew-Mei Huang Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

John Hunt Division of Pharmaceutical Evaluation II, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Russell Katz Division of Neuropharmacology Drug Products, Office of Drug Evaluation I, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Kofi Kumi Division of Pharmaceutical Evaluation I, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Peter Langguth Johannes Gutenberg-University, Germany

Lawrence J.Lesko Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Anthony Y.H.Lu Rutgers University, Piscataway, New Jersey, U.S.A.

Iftekhar Mahmood Center for Biologies Evaluation and Research, Rockville, Maryland, U.S.A.

Henry J.Malinowski Division of Pharmaceutical Evaluation II, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Patrick J.Marroum Division of Pharmaceutical Evaluation I, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Mehul U.Mehta Division of Pharmaceutical Evaluation I, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Andrea Meyerhoff* Department of Health and Human Services, Food and Drug Administration, Rockville, Maryland, U.S.A.

Rabindra N.Patnaikf Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Indra K.Reddy University of Arkansas for Medical Sciences; Little Rock, Arkansas, U.S.A.

Kellie Schoolar Reynolds^ Division of Pharmaceutical Evaluation III, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Barry Rosloff Division of Neuropharmacological Drug Products, Office of Drug Evaluation I, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Chandrahas Sahajwalla Division of Pharmaceutical Evaluation I, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

* Current affiliation: Clinical Associate Professor of Medicine, Division of Infectious Diseases,

Georgetown University, Washington, D.C., U.S.A. f Current affiliation: Executive Director, Biopharmaceutics, Watson Laboratories, Inc., Corona, California, U.S.A.

£ Current affiliation: Global Biopharmaceutics, Drug Metabolism and Pharmacokinetics, Aventis Pharmaceuticals, Bridgewater, New Jersey, U.S.A.

Tomas Salmonson Medical Products Agency, Uppsala, Sweden

Vanitha J.Sekar* Division of Pharmaceutical Evaluation I, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

W.Craig Simon Therapeutic Products Directorate, Health Canada, Ottawa, Ontario, Canada

Hilde Spahn-Langguth Martin-Luther-University, Halle-Wittenberg, Wolfgang-Langenbeck-Str., Germany

Maria Sunzelf Division of Pharmaceutical Evaluation I, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Veeneta Tandon Division of Pharmaceutical Evaluation I, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Kathleen Uhl Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Jashvant D.Unadkat Department of Pharamceutics, University of Washington, Seattle, Washington, U.S.A.

Ramana S.Uppoor Division of Pharmaceutical Evaluation I, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Jürgen Venitz Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia, U.S.A.

* Current affiliation: Aventis Pharmaceuticals, Bridgewater, New Jersey, U.S.A. f Current affiliation: Director, Clinical Pharmacology, Experimental Medicine, AstraZeneca LP, Wilmington, Delaware, U.S.A.

Xiaoxiong Wei Division of Pharmaceutical Evaluation II, Office of Clinical Pharmacology and Biopharmaceutics, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, Maryland, U.S.A.

Agnes M.Westelinck* Division of Pharmaceutical Evaluation II, Office of Clinical Pharmacology and Biopharmaceutics, Food and Drug Administration, Rockville, Maryland, U.S.A.

* Current affiliation: Barrier Therapeutics, Princeton, New Jersey, U.S.A.

Was this article helpful?

0 0

Post a comment